Cube Labs S.p.A., an Italian venture builder specializing in healthcare technologies and listed on Euronext Growth Milan, announced that its startups Adamas Biotech and DTech have won the call for proposals from the National Biodiversity Future Center (NBFC), coordinated by the National Research Council (CNR). Both startups, 51% owned by Cube Labs, received significant funding, amounting to €405,806 and €373,606 respectively, to develop innovative technologies in the biotechnology and healthcare sectors.

Project Details

Adamas Biotech presented a project focused on developing a nutraceutical based on catechins and probiotics, as well as a digital platform to support the maintenance of intestinal physiological functions and manage Irritable Bowel Syndrome (IBS). The funds will be used to advance the project from a TRL 6 to a TRL 8 by conducting a clinical study to demonstrate the safety of the combined product, with the aim of filing a new patent. Additionally, sustainable FSC-certified packaging will be developed, along with a pilot production batch, accompanied by a digital kit to facilitate communication between doctors and patients suffering from IBS.

DTech, on the other hand, proposed the development of a protective biospray against pollutants and microorganisms in the oro-nasal cavities, based on green tea catechins. The project also involves the creation of a hydrogel and a digital platform for communication between users and healthcare professionals. The funds will be used to advance the project from a TRL 4 to a TRL 8, with a Proof of Concept on volunteers during flu peaks or in environments with high PM10 levels. The biospray will be developed according to regulatory standards to obtain CE marking registration and FSC certification for sustainable packaging. Additionally, a digital platform will be developed, including an app for personalized medicine with dosage recommendations for inhaled sprays based on environmental parameters and bio-parameters detected by the software.

Comments

Filippo Surace, CEO and founder of Cube Labs, stated: “This prestigious recognition serves as a valid confirmation of the technology and applied research in our portfolio. The funding will allow Adamas Biotech and DTech to accelerate their R&D activities towards market access.” He also emphasized that Cube Labs was created to promote innovation and technology transfer processes in the Life Sciences sector, leveraging its innovative venture building model.

Source: Sanità33